These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 38288881)
1. Virology and safety profile of Molnupiravir at three different doses for treatment of SARS-CoV-2: a systematic review and meta-analysis. Sukaina M; Shuja SH; Rehan ST; Ochani S; Sheryar M APMIS; 2024 Mar; 132(3):139-151. PubMed ID: 38288881 [TBL] [Abstract][Full Text] [Related]
2. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. Jayk Bernal A; Gomes da Silva MM; Musungaie DB; Kovalchuk E; Gonzalez A; Delos Reyes V; Martín-Quirós A; Caraco Y; Williams-Diaz A; Brown ML; Du J; Pedley A; Assaid C; Strizki J; Grobler JA; Shamsuddin HH; Tipping R; Wan H; Paschke A; Butterton JR; Johnson MG; De Anda C; N Engl J Med; 2022 Feb; 386(6):509-520. PubMed ID: 34914868 [TBL] [Abstract][Full Text] [Related]
3. Safety of RNA-Dependent RNA Polymerase Inhibitors, Molnupiravir and VV116, for Oral Treatment of COVID-19: A Meta-Analysis. Zheng Z; Zhou J; Song Y Iran J Med Sci; 2024 May; 49(5):275-285. PubMed ID: 38751873 [TBL] [Abstract][Full Text] [Related]
4. Molnupiravir: A new candidate for COVID-19 treatment. Pourkarim F; Pourtaghi-Anvarian S; Rezaee H Pharmacol Res Perspect; 2022 Feb; 10(1):e00909. PubMed ID: 34968008 [TBL] [Abstract][Full Text] [Related]
5. Real-world effectiveness of molnupiravir, azvudine and paxlovid against mortality and viral clearance among hospitalized patients with COVID-19 infection during the omicron wave in China: A retrospective cohort study. Chen Y; Lin Y; Lu H; Wu X; Pan Y; Xia A; Pang L; Ye W; Xu F Diagn Microbiol Infect Dis; 2024 Aug; 109(4):116353. PubMed ID: 38776665 [TBL] [Abstract][Full Text] [Related]
6. Molnupiravir in COVID-19: A systematic review of literature. Singh AK; Singh A; Singh R; Misra A Diabetes Metab Syndr; 2021; 15(6):102329. PubMed ID: 34742052 [TBL] [Abstract][Full Text] [Related]
7. The combined treatment of Molnupiravir and Favipiravir results in a potentiation of antiviral efficacy in a SARS-CoV-2 hamster infection model. Abdelnabi R; Foo CS; Kaptein SJF; Zhang X; Do TND; Langendries L; Vangeel L; Breuer J; Pang J; Williams R; Vergote V; Heylen E; Leyssen P; Dallmeier K; Coelmont L; Chatterjee AK; Mols R; Augustijns P; De Jonghe S; Jochmans D; Weynand B; Neyts J EBioMedicine; 2021 Oct; 72():103595. PubMed ID: 34571361 [TBL] [Abstract][Full Text] [Related]
8. A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes. Sanderson T; Hisner R; Donovan-Banfield I; Hartman H; Løchen A; Peacock TP; Ruis C Nature; 2023 Nov; 623(7987):594-600. PubMed ID: 37748513 [TBL] [Abstract][Full Text] [Related]
9. Molnupiravir for the treatment of COVID-19 outpatients: An updated meta-analysis. Cheema HA; Abdul Rab S; Butt M; Jafar U; Shahid A; Rehman AU; Lee KY; Sahra S; Sah R J Microbiol Immunol Infect; 2024 Jun; 57(3):396-402. PubMed ID: 38555274 [TBL] [Abstract][Full Text] [Related]
11. Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID-19: A systematic review and meta-analysis. Amani B; Amani B Immun Inflamm Dis; 2024 Apr; 12(4):e1262. PubMed ID: 38652021 [TBL] [Abstract][Full Text] [Related]
12. Effect of molnupiravir on SARS-CoV-2 evolution in immunocompromised patients: a retrospective observational study. Fountain-Jones NM; Vanhaeften R; Williamson J; Maskell J; Chua IJ; Charleston M; Cooley L Lancet Microbe; 2024 May; 5(5):e452-e458. PubMed ID: 38527471 [TBL] [Abstract][Full Text] [Related]
13. An updated practical guideline on use of molnupiravir and comparison with agents having emergency use authorization for treatment of COVID-19. Singh AK; Singh A; Singh R; Misra A Diabetes Metab Syndr; 2022 Feb; 16(2):102396. PubMed ID: 35051686 [TBL] [Abstract][Full Text] [Related]
14. RdRp inhibitors and COVID-19: Is molnupiravir a good option? Hashemian SMR; Pourhanifeh MH; Hamblin MR; Shahrzad MK; Mirzaei H Biomed Pharmacother; 2022 Feb; 146():112517. PubMed ID: 34902743 [TBL] [Abstract][Full Text] [Related]
15. Human genetic risk of treatment with antiviral nucleoside analog drugs that induce lethal mutagenesis: The special case of molnupiravir. Waters MD; Warren S; Hughes C; Lewis P; Zhang F Environ Mol Mutagen; 2022 Jan; 63(1):37-63. PubMed ID: 35023215 [TBL] [Abstract][Full Text] [Related]